Fulcrum Therapeutics, Inc. (FULC) analyst actions
Rating and price-target actions on FULC in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the FULC overview →
4 measured FULC analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | Press release | +1.35% | +2.17% | |
| Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | Press release | +0.16% | +0.96% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | Press release | -0.25% | -7.14% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc.(FULC) And Encourages Stockholders to Reach Out | Press release | -3.05% | -5.75% |
Keep exploring
More FULC: earnings → · SEC filings → · FULC overview →